← back to search

Meagan Montesion

Tufts University · US
Area of research
Cancer Research · Oncology
Research interest
Research interests include Medicine, Cancer research, Immunotherapy, Internal medicine, Oncology, and Biology.
h-index
citations
1,052
works
10
NIH funding
primary concept
email

Recent publications

A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas
Nature Communications 2025cited by 6position: middledoi
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Nature 2024cited by 145position: middledoi
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non–Small-Cell Lung Cancer
Journal of Clinical Oncology 2024cited by 32position: middledoi
A diverse landscape of FGFR alterations and co-mutations defines novel therapeutic strategies in pediatric low-grade gliomas
bioRxiv (Cold Spring Harbor Laboratory) 2024cited by 4position: middledoi
Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations
ESMO Open 2022cited by 37position: middledoi
Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
Journal of Immunotherapy and Precision Oncology 2022cited by 31position: middledoi
Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non–Small-Cell Lung Cancer
JCO Precision Oncology 2021cited by 16position: middledoi
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
JCI Insight 2019cited by 535position: middledoi
Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma
Journal of Clinical Investigation 2019cited by 208position: middledoi
Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness
Cancer Immunology Research 2019cited by 38position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Razelle Kurzrock · Froedtert Hospital2 papers (2019–2022)Garrett M. Frampton · GlobalFoundries (United States)2 papers (2019–2019)Aaron M. Goodman · Moores Cancer Center2 papers (2019–2022)Ryosuke Okamura · Kyoto University Hospital2 papers (2019–2022) · 2 papers (2019–2022)Ali McBride · University of Arizona1 papers (2021–2021)Elizabeth M. Jaffee · NYU Langone Health1 papers (2019–2019)Nicholas Bevins · RAM Laboratories (United States)1 papers (2022–2022)Halla Nimeiri · Tempus Labs (United States)1 papers (2022–2022) · 1 papers (2022–2022) · 1 papers (2022–2022)Nilofer S. Azad · Bloomberg (United States)1 papers (2019–2019)Ole Gjoerup · Boston Foundation1 papers (2022–2022)Jacob J. Adashek · Center for Cancer Research1 papers (2022–2022)Teena Vithayathil · Sidney Kimmel Comprehensive Cancer Center1 papers (2019–2019) · 1 papers (2021–2021)Mark Yarchoan · Molecular Oncology (United States)1 papers (2019–2019)Arndt Vogel · Federal Institute for Risk Assessment1 papers (2022–2022)Ranajoy Chattopadhyay · Research Applications (United States)1 papers (2019–2019) · 1 papers (2021–2021)